Healthcare Cybersecurity Market Expected to Quadruple by 2034 at 14.8% CAGR The Global Healthcare Cybersecurity Market is projected to grow from US$ 18.0 billion in 2024 to around US$ 71.4 billion by 2034, registering a CAGR of 14.8% during 2025–2034. View more: https://market.us/report/healthcare-cybersecurity-market/

Healthcare Software As A Service Market Valued at USD 26.8 Billion in 2024 The Global Healthcare Software as a Service (SaaS) Market is projected to grow from US$ 26.8 billion in 2024 to US$ 146.3 billion by 2034, at a CAGR of 18.5%. View more: https://market.us/report/healthcare-software-as-a-service-market/

Healthcare Gamification Market Shows Strong 23.1% CAGR From 2025 to 2034 The Global Healthcare Gamification Market is projected to grow from US$ 4.7 billion in 2024 to US$ 37.6 billion by 2034, at a CAGR of 23.1%. View more: https://market.us/report/global-healthcare-gamification-market/

Healthcare Construction Market Predicted to Grow Steadily at 4.5% CAGR Through 2034 The Global Healthcare Construction Market is projected to reach US$ 442.0 billion by 2034, up from US$ 284.6 billion in 2024, growing at a CAGR of 4.5% from 2025 to 2034. View more: https://market.us/report/healthcare-construction-market/

🌍 Oxygen Therapy Equipment Market: Breathing New Life into Healthcare 🌬️ The Oxygen Therapy Equipment Market is expanding rapidly, driven by rising respiratory disorders, aging populations, and advancements in portable oxygen devices. As global health systems adapt to chronic conditions and home care trends, understanding this market’s dynamics is crucial for investors, healthcare providers, and manufacturers. 📌 For detailed insights, visit our website: https://www.reportprime.com/home-oxygen-therapy-equipment-r11005 Our official website: https://www.reportprime.com/

‼️Presentato in Tribunale dell’Unione Europea ricorso di annullamento dell’autorizzazione della sostanza sperimentale altamente pericolosa KOSTAIVE-Zapomeran, basata sull’RNA autoamplificante, con richiesta di provvedimento cautelare. MASSIMA DIFFUSIONE! Il 9 giugno 2025, nella mia funzione istituzionale di membro del Consiglio Provinciale del Sudtirolo/Alto Adige, ho presentato al Tribunale dell’Unione Europea un ricorso di annullamento ai sensi dell’articolo 263 TFUE contro la decisione della Commissione europea del 12 febbraio 2025 con cui è stata autorizzata come “vaccino”-Covid-19 la sostanza sperimentale KOSTAIVE-Zapomeran, basata sull’ingegneria genetica e costituita da RNA auto-amplificante. L’autorizzazione di KOSTAIVE è stata concessa senza che fossero stati effettuati studi essenziali per le sostanze basate sull’ingegneria genetica. Per KOSTAIVE non sono stati studiati né esclusi la genotossicità, la carcinogenicità, la mutagenicità (alterazione del DNA), né la trasmissibilità all’ambiente. Ciò è stato possibile perché nel 2009 la Commissione europea, sotto la presidenza di Josè Emanuel Barroso, ha escluso le sostanze dichiarate formalmente come “vaccini contro le malattie infettive” dall’applicazione delle severe norme di autorizzazione previste per i prodotti di terapia genica, a seguito dell’intervento dell’industria farmaceutica. I dettagli e i documenti relativi a questo procedimento criminale sono contenuti nel ricorso di annullamento. Non sorprende, quindi, che l’allora presidente della Commissione europea Barroso sia ora i CEO dell’alleanza per i vaccini GAVI e quindi il massimo lobbista dell’industria dei vaccini. Il KOSTAIVE comporta gravi rischi per la salute e la vita della popolazione dell’UE. Già dal foglietto illustrativo emerge che esiste il rischio di miocardite e pericardite. Esperti in posizioni istituzionali, come il direttore del Centro Nazionale per la Salute Globale presso l’Istituto Superiore di Sanità, temono che l’RNA auto-amplificante di KOSTAIVE possa essere trasmesso attraverso vescicole extracellulari (EV) all’intero ambiente, e dunque anche alle persone non trattate con KOSTAIVE e a tutti gli animali (le EV non conoscono barriere di specie). Il rispettivo articolo scientifico pubblicato dal dott. Maurizio Federico (e finanziato dal Ministero della Salute) è stato allegato come doc. 6 al ricorso di annullamento. Pertanto, il principio della necessità del libero consenso al trattamento farmacologico, sancito dal diritto internazionale, dal diritto dell’Unione Europea e dalle Carte Costituzionali degli Stati membri dell’Unione Europea, è stato di fatto abolito dalla Commissione Europea con l’autorizzazione di questa pericolosa sostanza sperimentale geneticamente modificata con rilevanza penale! I motivi per cui in questo caso ogni singolo cittadino dell’UE ha la legittimazione ad agire dinanzi al Tribunale europeo sono riportati in dettaglio nel ricorso di annullamento. Data l’estrema urgenza della questione (è in gioco la salute e la vita di tutti i cittadini dell’UE!), è stata presentata anche un’istanza di provvedimento cautelare e la richiesta per l’adozione del procedimento accelerato. I cittadini dell’UE, rappresentati da avvocati, possono partecipare al procedimento, che pende con T-375/27, in qualità di intervenienti. ‼️Lawsuit Filed at the European Union Court to Annul Authorization of the Highly Dangerous Experimental Substance KOSTAIVE-Zapomeran, Based on Self-Amplifying RNA, with Request for Interim Measures On June 9, 2025, in my official capacity as a member of the Provincial Council of South Tyrol/Alto Adige, I filed an annulment lawsuit under Article 263 TFEU at the Court of Justice of the European Union against the European Commission’s decision of February 12, 2025, which authorized the experimental substance KOSTAIVE-Zapomeran—a genetically engineered, self-amplifying RNA-based product—as a "Covid-19 vaccine." The authorization of KOSTAIVE was granted **without conducting essential studies required for genetically engineered substances. For **KOSTAIVE, genotoxicity, carcinogenicity, mutagenicity (DNA alteration), and environmental transmission were neither studied nor ruled out. This was possible because, in 2009, under the presidency of José Manuel Barroso, the European Commission excluded substances formally declared as "vaccines against infectious diseases" from the strict authorization rules applied to gene therapy products, following pressure from the pharmaceutical industry. The details and documents regarding this criminal proceeding are included in the annulment lawsuit. Unsurprisingly, the former European Commission President Barroso is now the CEO of the vaccine alliance GAVI and thus the top lobbyist for the vaccine industry. KOSTAIVE poses serious risks to the health and lives of EU citizens. Even the package leaflet acknowledges the risk of myocarditis and pericarditis. Experts in institutional positions, such as the Director of the National Center for Global Health at the Italian National Health Institute (Istituto Superiore di Sanità), fear that the self-amplifying RNA in KOSTAIVE could be transmitted through extracellular vesicles (EVs) to the entire environment, including people not treated with KOSTAIVE and all animals (since EVs do not respect species barriers). The scientific article published by Dr. Maurizio Federico (and funded by the Italian Ministry of Health) was attached as Document 6 to the annulment lawsuit. Thus, the principle of free and informed consent to medical treatment, enshrined in international law, EU law, and the constitutions of EU member states, has been effectively abolished by the European Commission** through the authorization of this dangerous, genetically modified experimental substance, which carries potential criminal liability! The reasons why every single EU citizen has standing to bring this case before the European Court are detailed in the annulment lawsuit. Given the extreme urgency of the matter (the health and lives of all EU citizens are at stake!), a request for interim measures and an expedited procedure has also been filed. EU citizens, represented by lawyers, can join the proceedings (Case T-375/27) as interveners. https://www.renate-holzeisen.eu/it/presentato-ricorso-di-annullamento-dellautorizzazione-come-vaccino-della-sostanza-sperimentale-kostaive-zapomeran-con-istanza-cautelare/?amp=1

GATES SVELA LE CARTE: L'ID DIGITALE COME ARMA FINALE CONTRO IL LIBERO PENSIERO Eccolo di nuovo. L'architetto della sorveglianza globale, il profeta autoproclamato delle emergenze sanitarie, il miliardario che sussurra all'orecchio dei governi avanza l'ennesimo tassello del suo progetto tecnocratico. Bill Gates – che non si nasconde più dietro veli di filantropia – articola con disarmante chiarezza la prossima fase: un sistema di identificazione digitale per soffocare quella che lui chiama "disinformazione". "Gli Stati Uniti rappresentano un caso complesso a causa del Primo Emendamento. Quali eccezioni possiamo contemplare?" Non è una domanda, è una strategia. Il Primo Emendamento – questo fastidioso ostacolo alla censura totale – viene trattato come un bug da correggere nel sistema operativo della società che immagina. La sua rivelazione prosegue senza filtri: "Credo che col tempo... vorremmo operare in un ambiente dove le persone siano veramente identificate... Dovremo sviluppare sistemi e comportamenti che ci permettano di essere più consapevoli riguardo a chi dice cosa, chi ha creato questo contenuto." Traduzione: nessuna voce anonima, nessun rifugio digitale, nessuna opinione senza un collare elettronico che ne tracci la provenienza. L'uomo che ha costruito un impero sul controllo dei sistemi operativi ora ambisce al controllo dell'ecosistema informativo globale. Non è un'evoluzione inaspettata per chi segue la traiettoria di Gates. Dal dominio dei computer personali alla manipolazione dei sistemi alimentari globali, dall'influenza sulla sanità mondiale all'ingegneria climatica – il pattern è sempre lo stesso: centralizzazione, controllo, abolizione delle alternative. L'ID digitale rappresenta semplicemente l'anello mancante – il dispositivo che salda definitivamente persona fisica e identità digitale, trasformando ogni espressione umana in dato tracciabile, classificabile, eventualmente censurabile. La tecnocrazia di cui Gates è portavoce non ha bisogno di campi di concentramento o plotoni d'esecuzione. Le bastano database, algoritmi e l'eliminazione sistematica dell'anonimato. Il dissenso non viene fucilato – viene semplicemente reso invisibile, relegato negli angoli più oscuri e inaccessibili della rete, privato di ossigeno mediatico. Chi ha seguito l'ascesa di questa élite tecnocratica riconosce i segnali. Gates non sta improvvisando – sta eseguendo il copione previsto, rivelando pubblicamente ciò che è stato pianificato nelle stanze dei bottoni della governance globale. L'ID digitale non è uno strumento isolato – è il fulcro di un ecosistema di controllo che include moneta digitale, credito sociale e biosorveglianza permanente. La "lotta alla disinformazione" è solo il pretesto nobile dietro cui nascondere l'obiettivo reale: la fine definitiva della privacy e dell'autonomia individuale. La domanda non è più "se" ma "quando" questo sistema verrà implementato. E soprattutto: quale resistenza siamo disposti a opporre? GATES SHOWS HIS CARDS: DIGITAL ID AS THE ULTIMATE WEAPON AGAINST FREE THOUGHT Here he goes again. The architect of global surveillance, the self-proclaimed prophet of health emergencies, the billionaire who whispers in the ear of governments, advances yet another piece of his technocratic project. Bill Gates – no longer hiding behind veils of philanthropy – articulates with disarming clarity the next phase: a digital identification system to stifle what he calls “misinformation.” “The United States is a complex case because of the First Amendment. What exceptions can we contemplate?” It’s not a question, it’s a strategy. The First Amendment – ​​that pesky obstacle to total censorship – is treated as a bug to be fixed in the operating system of the society he imagines. His revelation continues without filters: "I think that over time... we would like to operate in an environment where people are truly identified... We will have to develop systems and behaviors that allow us to be more aware of who says what, who created this content." Translation: no anonymous voice, no digital refuge, no opinion without an electronic collar that traces its origin. The man who built an empire on the control of operating systems now aspires to control the global information ecosystem. This is not an unexpected evolution for those who follow Gates' trajectory. From the domination of personal computers to the manipulation of global food systems, from influencing global health to climate engineering – the pattern is always the same: centralization, control, abolition of alternatives. The digital ID is simply the missing link – the device that definitively welds the physical person and digital identity, transforming every human expression into traceable, classifiable, possibly censorable data. The technocracy that Gates champions does not need concentration camps or firing squads. Databases, algorithms, and the systematic elimination of anonymity are enough. Dissent is not shot – it is simply made invisible, relegated to the darkest and most inaccessible corners of the internet, deprived of media oxygen. Anyone who has followed the rise of this technocratic elite recognizes the signs. Gates is not improvising – he is following the expected script, publicly revealing what has been planned in the control rooms of global governance. The digital ID is not an isolated tool – it is the centerpiece of an ecosystem of control that includes digital currency, social credit, and permanent biosurveillance. The "fight against disinformation" is just the noble pretext behind which to hide the real goal: the definitive end of privacy and individual autonomy. The question is no longer "if" but "when" this system will be implemented. And above all: what resistance are we willing to put up? t.me/lacivettabianca

The global Respiratory Care Devices Market is poised for significant expansion over the coming decade, driven by rising prevalence of chronic respiratory diseases, technological advancements in respiratory monitoring, and a growing geriatric population. As respiratory conditions like COPD (Chronic Obstructive Pulmonary Disease), asthma, and sleep apnea become more widespread, the demand for both in-hospital and home respiratory monitoring solutions is set to escalate. The global respiratory care devices market size is expected to reach USD 44.96 billion by 2032, according to a new study by Polaris Market Research. 🌍 Market Overview Respiratory care devices are used in the diagnosis, treatment, and monitoring of patients with respiratory conditions. These devices play a critical role in managing both acute and chronic respiratory diseases, offering solutions such as oxygen concentrators, nebulizers, inhalers, CPAP devices, and ventilator devices. With the advent of non-invasive and smart connected equipment, patient care is becoming more efficient, personalized, and accessible. The COVID-19 pandemic served as a catalyst for the global respiratory devices market, dramatically increasing the demand for mechanical ventilators and oxygen therapy equipment. Although the pandemic has waned, awareness of respiratory health has surged, fostering sustained demand for pulmonary therapy equipment across hospitals, clinics, and home care settings. 🚀 Key Market Growth Drivers Surging Prevalence of Chronic Respiratory Diseases The increasing global burden of chronic respiratory diseases, particularly asthma and COPD, is a major factor driving market growth. According to the World Health Organization, over 300 million people suffer from asthma, and COPD is projected to become the third leading cause of death globally. Aging Global Population The global population aged 65 and above is growing rapidly. Older adults are more susceptible to respiratory conditions, necessitating the use of advanced monitoring and therapeutic devices. This demographic trend is expected to significantly boost market demand, particularly in developed economies. Technological Advancements and Smart Devices Integration of AI, IoT, and wireless technologies in respiratory care is revolutionizing the market. Devices now offer real-time monitoring, remote diagnostics, and enhanced patient compliance, making home respiratory monitoring increasingly feasible and effective. Post-COVID Healthcare Infrastructure Development The global healthcare system has witnessed heavy investments in critical care infrastructure post-COVID-19. Countries have bolstered their inventories of ventilator devices and oxygen supplies, creating a permanent demand baseline for emergency preparedness. Shift Toward Home-Based Care Patient preference for home care, cost-efficiency, and insurance support are encouraging the adoption of compact, portable respiratory solutions. Devices like portable oxygen concentrators and wearable respiratory monitors are seeing rising popularity. ⚠️ Market Challenges Despite strong growth potential, the respiratory care devices market faces several challenges: High Cost of Equipment: Advanced respiratory equipment, especially smart and portable devices, come at a high price, limiting accessibility in low-income regions. Reimbursement and Regulatory Hurdles: Inconsistent reimbursement policies across different countries and stringent regulatory requirements can hinder market expansion, particularly for new entrants. Device Maintenance and Calibration Issues: Regular maintenance, calibration, and user training are required for optimal functionality of respiratory devices, which may be challenging in remote or underserved areas. Lack of Skilled Healthcare Personnel: In many emerging markets, the shortage of trained professionals to operate complex devices like ventilators poses a major barrier. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/respiratory-care-devices-market 🌐 Regional Market Analysis North America North America remains the largest market for respiratory care devices, owing to its robust healthcare infrastructure, high awareness, and favorable reimbursement policies. The U.S. has witnessed significant growth in home respiratory monitoring due to its aging population and the rise of telehealth services. Europe Europe holds a substantial share, supported by high incidence rates of respiratory disorders, government healthcare funding, and technological adoption. Germany, the UK, and France lead the European market. Asia-Pacific The Asia-Pacific region is projected to experience the highest growth rate, driven by rising pollution levels, increasing smoking rates, and expanding healthcare access. Countries like China and India are investing heavily in healthcare modernization and local manufacturing of pulmonary therapy equipment. Latin America and Middle East & Africa These regions are gradually developing their healthcare systems. Brazil, South Africa, and Saudi Arabia are showing increasing demand for ventilator devices and diagnostic tools due to growing awareness and government initiatives. 🏢 Key Companies in the Respiratory Care Devices Market Several global and regional players dominate the respiratory care devices market. Key companies are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their positions. Philips Respironics (Koninklijke Philips N.V.) A major player in sleep and respiratory care, known for its CPAP machines, oxygen concentrators, and home respiratory monitoring solutions. ResMed Inc. Specializes in cloud-connected devices for sleep apnea and other chronic respiratory diseases. Its cloud-based platform helps patients and providers track and manage respiratory health remotely. Medtronic plc Offers a wide range of respiratory support products including mechanical ventilators and monitoring systems. Strong presence in hospitals and critical care settings. Fisher & Paykel Healthcare Known for innovative respiratory humidification and ventilation products, especially in neonatal and adult intensive care. Drägerwerk AG & Co. KGaA A German company with a strong foothold in critical care, especially mechanical ventilators and anesthesia workstations. GE Healthcare Provides advanced respiratory diagnostic imaging and ventilator support technologies. Collaborating with AI firms to enhance device intelligence. Vyaire Medical Inc. A specialist in respiratory diagnostics and ventilation solutions, especially popular among clinics and home care providers. 🔮 Future Outlook The future of the respiratory care devices market looks promising with the continued focus on non-invasive, intelligent, and personalized care. The rise of pulmonary therapy equipment that integrates wearable technology, remote access, and data analytics will significantly transform the way respiratory conditions are managed globally. Investments in R&D, coupled with strong collaborations between med-tech firms and healthcare providers, are expected to yield groundbreaking innovations in the coming years. Meanwhile, the adoption of green technologies and sustainability practices in device manufacturing is gaining traction to address environmental concerns. 📌 Conclusion In conclusion, the global respiratory care devices market is entering a transformative phase, fueled by medical necessity, technological innovation, and changing healthcare delivery models. With robust growth across both developed and emerging markets, the sector offers ample opportunities for investors, manufacturers, and healthcare providers alike. As chronic respiratory illnesses continue to burden health systems worldwide, the emphasis on early diagnosis, personalized therapy, and accessible care will remain at the heart of respiratory device development. More Trending Latest Reports By Polaris Market Research: Voluntary Carbon Credit Market Precision Swine Farming Market D-Dimer Testing Market Flame Retardants Market Wax Melts Market Europe Facial Injectables Market Reverse Osmosis (RO) Membrane Market Electrolytic Manganese Dioxide Market Cyber Security Market

ANCHE L'INDIA FUORI DALL' OMS?? . INDIA 02/12/2023 . "L'OMS ha perso la sua indipendenza, il governo indiano dovrebbe uscire dall'organismo sanitario mondiale". https://m.economictimes.com/news/india/who-has-lost-its-independence-indian-govt-should-exit-global-health-body/articleshow/105678716.cms

https://www.databridgemarketresearch.com/ar/reports/global-healthcare-automatic-identification-and-data-capture-market